These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28945981)

  • 1. A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.
    St-Gallay SA; Bennett N; Critchlow SE; Curtis N; Davies G; Debreczeni J; Evans N; Hardern I; Holdgate G; Jones NP; Leach L; Maman S; McLoughlin S; Preston M; Rigoreau L; Thomas A; Turnbull AP; Walker G; Walsh J; Ward RA; Wheatley E; Winter-Holt J
    SLAS Discov; 2018 Jan; 23(1):11-22. PubMed ID: 28945981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
    Brooke DG; van Dam EM; Watts CK; Khoury A; Dziadek MA; Brooks H; Graham LJ; Flanagan JU; Denny WA
    Bioorg Med Chem; 2014 Feb; 22(3):1029-39. PubMed ID: 24398380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships.
    Wang Y; Qu C; Liu T; Wang C
    Eur J Med Chem; 2020 Oct; 203():112612. PubMed ID: 32679452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
    Clem BF; O'Neal J; Tapolsky G; Clem AL; Imbert-Fernandez Y; Kerr DA; Klarer AC; Redman R; Miller DM; Trent JO; Telang S; Chesney J
    Mol Cancer Ther; 2013 Aug; 12(8):1461-70. PubMed ID: 23674815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
    Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y
    J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.
    Boutard N; Białas A; Sabiniarz A; Guzik P; Banaszak K; Biela A; Bień M; Buda A; Bugaj B; Cieluch E; Cierpich A; Dudek Ł; Eggenweiler HM; Fogt J; Gaik M; Gondela A; Jakubiec K; Jurzak M; Kitlińska A; Kowalczyk P; Kujawa M; Kwiecińska K; Leś M; Lindemann R; Maciuszek M; Mikulski M; Niedziejko P; Obara A; Pawlik H; Rzymski T; Sieprawska-Lupa M; Sowińska M; Szeremeta-Spisak J; Stachowicz A; Tomczyk MM; Wiklik K; Włoszczak Ł; Ziemiańska S; Zarębski A; Brzózka K; Nowak M; Fabritius CH
    ChemMedChem; 2019 Jan; 14(1):169-181. PubMed ID: 30378281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.
    Seo M; Kim JD; Neau D; Sehgal I; Lee YH
    PLoS One; 2011; 6(9):e24179. PubMed ID: 21957443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
    Clem B; Telang S; Clem A; Yalcin A; Meier J; Simmons A; Rasku MA; Arumugam S; Dean WL; Eaton J; Lane A; Trent JO; Chesney J
    Mol Cancer Ther; 2008 Jan; 7(1):110-20. PubMed ID: 18202014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-throughput screening campaign against PFKFB3 identified potential inhibitors with novel scaffolds.
    Li J; Zhou Y; Eelen G; Zhou QT; Feng WB; Labroska V; Ma FF; Lu HP; Dewerchin M; Carmeliet P; Wang MW; Yang DH
    Acta Pharmacol Sin; 2023 Mar; 44(3):680-692. PubMed ID: 36114272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
    Imbert-Fernandez Y; Clem BF; O'Neal J; Kerr DA; Spaulding R; Lanceta L; Clem AL; Telang S; Chesney J
    J Biol Chem; 2014 Mar; 289(13):9440-8. PubMed ID: 24515104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3).
    Emini Veseli B; Perrotta P; Van Wielendaele P; Lambeir AM; Abdali A; Bellosta S; Monaco G; Bultynck G; Martinet W; De Meyer GRY
    FEBS Lett; 2020 Sep; 594(18):3067-3075. PubMed ID: 32620030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
    O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
    Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating combinatorial approaches in virtual screening on human inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a case study for small molecule kinases.
    Crochet RB; Cavalier MC; Seo M; Kim JD; Yim YS; Park SJ; Lee YH
    Anal Biochem; 2011 Nov; 418(1):143-8. PubMed ID: 21771574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.
    Ozcan SC; Mutlu A; Altunok TH; Gurpinar Y; Sarioglu A; Guler S; Muchut RJ; Iglesias AA; Celikler S; Campbell PM; Yalcin A
    Biochem Biophys Res Commun; 2021 Sep; 571():118-124. PubMed ID: 34325126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells.
    Kallal LA; Waszkiewicz A; Jaworski JP; Della Pietra A; Berrodin T; Brady P; Jurewicz AJ; Zeng X; Payne L; Medina JR; Doepner-Buser C; Mangatt B
    SLAS Discov; 2021 Feb; 26(2):216-229. PubMed ID: 33482073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
    Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
    J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis.
    Zou Y; Zeng S; Huang M; Qiu Q; Xiao Y; Shi M; Zhan Z; Liang L; Yang X; Xu H
    Br J Pharmacol; 2017 May; 174(9):893-908. PubMed ID: 28239846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
    Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
    Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.
    Gustafsson NMS; Färnegårdh K; Bonagas N; Ninou AH; Groth P; Wiita E; Jönsson M; Hallberg K; Lehto J; Pennisi R; Martinsson J; Norström C; Hollers J; Schultz J; Andersson M; Markova N; Marttila P; Kim B; Norin M; Olin T; Helleday T
    Nat Commun; 2018 Sep; 9(1):3872. PubMed ID: 30250201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
    Pyrkov TV; Sevostyanova IA; Schmalhausen EV; Shkoporov AN; Vinnik AA; Muronetz VI; Severin FF; Fedichev PO
    ChemMedChem; 2013 Aug; 8(8):1322-9. PubMed ID: 23813838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.